Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Inclusion Criteria: * Ages 18-70 years * One of the following: * Patients undergoing autologous stem cell transplantation (ASCT) or any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product for: * High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc * Large B-cell lymphoma with a history of secondary CNS involvement * Histologic transformation of indolent lymphoma to large B-cell lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic leukemia, or Waldenstrom macroglobulinemia * High risk international prognostic index (IPI) score 4 or 5, at diagnosis or prior to CAR T-cell leukapheresis * Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for large B-cell lymphoma * Eastern Cooperative Oncology Group (ECOG) 0-2 * Requirements for post-ASCT and post-alloHCT participants: * Disease status of partial response (PR) or complete response (CR) prior to transplantation * Receive reduced-intensity conditioning regimen * Enrollment no later than day +90 * Requirements for post-CAR T-cell therapy participants: * Disease status of PR or CR after post-CAR T-cell therapy positron emission tomography (PET)-computed tomography (CT) at 1-3 months * Enrollment no later than day +104 * Ability to give full informed consent * Female…